PPi HC provides outstanding Health/Pharmacoeconomic capabilities. PPi HC draws from our experienced team of specialists well versed in setting up and conducting all types of pharmacoeconomic evaluations as described, both prospectively and retrospectively. This international team includes health economists, quality of life and  physicians, statisticians, clinical research associates, project managers and psycho motor specialists, many of whom have over 25 years of experience.

Pharmacoeconomics centres on the economic evaluation of health technologies such as pharmaceuticals and medical devices, and can use a variety of analysis formats such as BIA (= Budget Impact Analysis), CEA (= Cost Effectiveness Analysis) or CUA (Cost Utility Analysis). QALY's ( = Quality Adjusted Life Years) have become the dominant outcome of interest in pharmacoeconomic evaluations, and many studies employ a "Cost per QALY"  analysis. Economic evaluations are often carried out alongside RCT's ( = Randomized Clinical Trials) and using methods of decision-analytic modelling. As more expensive drugs and medical devices are being developed and licensed, it has become imperative to apply the principles of pharmacoeconomics in order to maximise improvement in (quality of) life at a reasonable cost.

A typical PPi HC pharmacoeconomic project will be the development of a pharmacoeconomic model based on the clinical profile of a new technology, populated with local health care resource data from a basket of EU and other countries. Studies like these may be used as input for Core Value- and Pricing and Reimbursement Dossiers, but also macro budget impact assessment and technology benchmarking, among others.